These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31017664)

  • 1. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
    George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
    Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.
    Zakeri K; Narayanan D; Prasanna PGS; Vikram B; Buchsbaum JC
    Radiat Res; 2020 May; 193(5):425-434. PubMed ID: 32216707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
    He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
    Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.
    Vatner R; James CD; Sathiaseelan V; Bondra KM; Kalapurakal JA; Houghton PJ
    Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28439. PubMed ID: 32827353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
    Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
    J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
    Spagnoletti G; Li Bergolis V; Piscazzi A; Giannelli F; Condelli V; Sisinni L; Bove G; Storto G; Landriscina M
    Tumour Biol; 2018 Apr; 40(4):1010428318770957. PubMed ID: 29663854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
    Jeong YK; Kim MS; Lee JY; Kim EH; Kim W; Ha H; Jeong JH
    Tumori; 2013; 99(2):176-82. PubMed ID: 23748811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
    Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
    Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
    Saelen MG; Ree AH; Kristian A; Fleten KG; Furre T; Hektoen HH; Flatmark K
    Radiat Oncol; 2012 Sep; 7():165. PubMed ID: 23017053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving role of neoadjuvant therapy in rectal cancer.
    Schrag D
    Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination effect of cetuximab with radiation in colorectal cancer cells.
    Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
    Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
    Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
    Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
    Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdörfer F; de Leve S; Jendrossek V
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basics to advances in nanotherapy of colorectal cancer.
    Tiwari A; Saraf S; Jain A; Panda PK; Verma A; Jain SK
    Drug Deliv Transl Res; 2020 Apr; 10(2):319-338. PubMed ID: 31701486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.